Anti-CD3 immunohistochemistry (IHC) analysis of the tumor tissues revealed poor infiltration of anti-CEA scFab CAR-T cells in the CAR-T only treated group (Figure 5A) compared to their significant infiltration in the combined therapy group (Figure 5B). The gene discussed is CEACAM5; the disease is neoplasm.